SlideShare ist ein Scribd-Unternehmen logo
1 von 28
Downloaden Sie, um offline zu lesen
December 2011
Pharmacovigilance
Are you concerned enough?
What is Pharmacovigilance (PV)?
The science and activities relating to the detection, assessment,
understanding and prevention of adverse effects or any other
medicine-related problem
– World Health Organization
Pharmaco - Vigilance
 Pharmaco = medicine
 Vigilare = to watch
 alert watchfulness
 wakefulness
 watchfulness in respect of danger; care; caution; circumspection
 the process of paying close and continuous attention
Definition
 Adverse Drug Reaction
 "A response to a drug which is noxious and unintended, and which occurs at
doses normally used in man for the prophylaxis, diagnosis, or therapy of disease,
or for the modification of physiological function."
 Adverse Event
 Any untoward medical occurrence that may present during treatment with a
pharmaceutical product but which does not necessarily have a causal relationship
with this treatment
 Side Effect
 Any unintended effect of a pharmaceutical product occurring at doses normally
used in man which is related to the pharmacological properties of the drug
The Aims of Pharmacovigilance
 To improve patient care and safety
 To improve public health and safety
 To contribute to the assessment of benefit, harm,
effectiveness and risk of medicines
 To promote understanding, education and clinical training
What to Report?
SERIOUS ADRS
 A serious adverse event (experience) or reaction is any
untoward medical occurrence that at any dose:
 results in death,
 is life-threatening,
 requires inpatient hospitalization of prolongation of existing
hospitalization,
 is a congenital anomaly/birth defect.
NOTE: The term “life-threatening” in the definition of “serious” refers to an event
in which the patient was at risk of death at the time of the event; it does not
refer to an event which hypothetically might have caused death if it was more
severe.
Adverse Reactions:Possible Causes
 Intrinsic factors of the drug
 Pharmacological
 Idiosyncratic
 Carcinogenicity, Mutagenicity
 Teratogenicity
 Extrinsic factors
 Adulterants
 Contamination
 Underlying medical conditions
 Interactions
 Wrong usage
What Should be Reported
 New drugs
 Report all suspected reactions including minor ones
 For established or well known drugs
 All serious, unexpected, unusual ADRs
 Change in frequency of a given reaction
 ADRs to generics not seen with innovator products
 ADRs to traditional medicines
What Should be Reported
 All suspected drug-drug, drug-food, drug-food supplement
interactions
 Statement highlighting marine source of supplements such
as glucosamine so that can be avoided by those with allergy
to sea food
 ADRs associated with drug withdrawals
 ADRs due to medication errors
 eg vincristine given IT
 ADRs due to lack of efficacy or suspected pharmaceutical
defects
Why ADRs are important ?
 5% of hospital admissions
 Death of 1 in 1000 medical inpatients
 Complicates drug therapy
 Decrease compliance
Why ADRs are important ?
30 – 50% of all ADRs are preventable
Why do we need
pharmacovigilance?
Why do we need
pharmacovigilance?
Reason 1:
 Humanitarian concern –
 Insufficient evidence of safety from clinical trials
 Animal experiments
 Phase 1 – 3 studies prior to marketing authorization
Why do we need
pharmacovigilance?
Reason 2
 Medicines are supposed to save lives
 Dying from a disease is sometimes unavoidable; dying from a
medicine is unacceptable.
WHO. Geneva 2005
Why do we need
pharmacovigilance?
Reason 3: ADRs are expensive !!
 6.5% of admissions are due to ADRs
 Seven 800-bed hospitals are occupied by ADR patients
Cost of ADRs ?
 ADR related cost to the country exceeds the cost of the
medications themselves
Why do we need
pharmacovigilance?
Reason 4:
 Promoting rational use of medicines and adherence
Pharmacovigilance system
 Records medication related errors
 Analyses those errors
 Implements interventions
 Promotes patient safety
 Prevent 'preventable errors'
Actionable learning system
ARGUS – ARIS Global – Phase Forward (Empirica)
Passive - Proactive
Future Pro-Active State
Risk
Management
Aggregate
Reporting
Signal Detection
Adverse Case
Management
Passive - Proactive
Current Passive State
Risk
Management
Signal Detection
Aggregate
Reporting
What can we do?
What can we do?
 Develop procedures for the identification, reporting and
follow up of adverse drug events
What can we do?
 Assess the current technology used in the drug safety process
and assist in implementation of new systems
What can we do?
 Evaluate data quality and data integrity controls in place
What can we do?
 Prepare risk minimization action plan (RiskMAP)
What can we do?
 Assess current drug safety and pharmacovigilance training
programs
What can we do?
 Reconcile internal processes for recording safety data received
from multiple sources
For more information:
Monica Dema, Manager New
Business Development
973.658.3133
Or
Monica.Dema@RCMT.com
Or
@MonicaDema

Weitere ähnliche Inhalte

Ähnlich wie pharmacovigilance-111031093044-phpapp01.pdf

An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizorampougang golmei
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Understanding pharmacovigilance
Understanding pharmacovigilanceUnderstanding pharmacovigilance
Understanding pharmacovigilancefinenessinstitute
 
Adverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAdverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAjithJs2
 
Spontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxSpontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxDrRajeshHadia
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDYSuvarta Maru
 
Pharmacovigilance - an overview
Pharmacovigilance - an overview Pharmacovigilance - an overview
Pharmacovigilance - an overview S S Shiva
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance ANAhmed Nouri
 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance ASHUTOSH MISHRA
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Shaukat Patel MS R.Ph.
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Shaukat Patel MS R.Ph.
 

Ähnlich wie pharmacovigilance-111031093044-phpapp01.pdf (20)

An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Understanding pharmacovigilance
Understanding pharmacovigilanceUnderstanding pharmacovigilance
Understanding pharmacovigilance
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Basics Of Pharmacovigilance
Basics Of PharmacovigilanceBasics Of Pharmacovigilance
Basics Of Pharmacovigilance
 
Adverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAdverse Drug Reactions.pptx
Adverse Drug Reactions.pptx
 
Spontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxSpontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDY
 
Pharmacovigilance System
Pharmacovigilance SystemPharmacovigilance System
Pharmacovigilance System
 
Pharmacovigilance - an overview
Pharmacovigilance - an overview Pharmacovigilance - an overview
Pharmacovigilance - an overview
 
Pv overview (2)
Pv overview (2)Pv overview (2)
Pv overview (2)
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)
 
Introduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptxIntroduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptx
 
Pharmacovigilence
PharmacovigilencePharmacovigilence
Pharmacovigilence
 

Mehr von dabloosaha

Institutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfInstitutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfdabloosaha
 
signaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfsignaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfdabloosaha
 
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxlecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxdabloosaha
 
guidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfguidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfdabloosaha
 
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdfdabloosaha
 
pv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfpv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfdabloosaha
 
aggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfaggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfdabloosaha
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdfdabloosaha
 
STUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfSTUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfdabloosaha
 

Mehr von dabloosaha (9)

Institutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfInstitutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdf
 
signaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfsignaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdf
 
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxlecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
 
guidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfguidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdf
 
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
 
pv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfpv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdf
 
aggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfaggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdf
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdf
 
STUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfSTUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdf
 

Kürzlich hochgeladen

Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhikauryashika82
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.pptRamjanShidvankar
 
Magic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxMagic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxdhanalakshmis0310
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...christianmathematics
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17Celine George
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Association for Project Management
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentationcamerronhm
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docxPoojaSen20
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseAnaAcapella
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin ClassesCeline George
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
Third Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxThird Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxAmita Gupta
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfSherif Taha
 

Kürzlich hochgeladen (20)

Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Magic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxMagic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptx
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Third Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxThird Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptx
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 

pharmacovigilance-111031093044-phpapp01.pdf

  • 2. What is Pharmacovigilance (PV)? The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem – World Health Organization
  • 3. Pharmaco - Vigilance  Pharmaco = medicine  Vigilare = to watch  alert watchfulness  wakefulness  watchfulness in respect of danger; care; caution; circumspection  the process of paying close and continuous attention
  • 4. Definition  Adverse Drug Reaction  "A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function."  Adverse Event  Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment  Side Effect  Any unintended effect of a pharmaceutical product occurring at doses normally used in man which is related to the pharmacological properties of the drug
  • 5. The Aims of Pharmacovigilance  To improve patient care and safety  To improve public health and safety  To contribute to the assessment of benefit, harm, effectiveness and risk of medicines  To promote understanding, education and clinical training
  • 6. What to Report? SERIOUS ADRS  A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:  results in death,  is life-threatening,  requires inpatient hospitalization of prolongation of existing hospitalization,  is a congenital anomaly/birth defect. NOTE: The term “life-threatening” in the definition of “serious” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.
  • 7. Adverse Reactions:Possible Causes  Intrinsic factors of the drug  Pharmacological  Idiosyncratic  Carcinogenicity, Mutagenicity  Teratogenicity  Extrinsic factors  Adulterants  Contamination  Underlying medical conditions  Interactions  Wrong usage
  • 8. What Should be Reported  New drugs  Report all suspected reactions including minor ones  For established or well known drugs  All serious, unexpected, unusual ADRs  Change in frequency of a given reaction  ADRs to generics not seen with innovator products  ADRs to traditional medicines
  • 9. What Should be Reported  All suspected drug-drug, drug-food, drug-food supplement interactions  Statement highlighting marine source of supplements such as glucosamine so that can be avoided by those with allergy to sea food  ADRs associated with drug withdrawals  ADRs due to medication errors  eg vincristine given IT  ADRs due to lack of efficacy or suspected pharmaceutical defects
  • 10. Why ADRs are important ?  5% of hospital admissions  Death of 1 in 1000 medical inpatients  Complicates drug therapy  Decrease compliance
  • 11. Why ADRs are important ? 30 – 50% of all ADRs are preventable
  • 12. Why do we need pharmacovigilance?
  • 13. Why do we need pharmacovigilance? Reason 1:  Humanitarian concern –  Insufficient evidence of safety from clinical trials  Animal experiments  Phase 1 – 3 studies prior to marketing authorization
  • 14. Why do we need pharmacovigilance? Reason 2  Medicines are supposed to save lives  Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. WHO. Geneva 2005
  • 15. Why do we need pharmacovigilance? Reason 3: ADRs are expensive !!  6.5% of admissions are due to ADRs  Seven 800-bed hospitals are occupied by ADR patients
  • 16. Cost of ADRs ?  ADR related cost to the country exceeds the cost of the medications themselves
  • 17. Why do we need pharmacovigilance? Reason 4:  Promoting rational use of medicines and adherence
  • 18. Pharmacovigilance system  Records medication related errors  Analyses those errors  Implements interventions  Promotes patient safety  Prevent 'preventable errors' Actionable learning system ARGUS – ARIS Global – Phase Forward (Empirica)
  • 19. Passive - Proactive Future Pro-Active State Risk Management Aggregate Reporting Signal Detection Adverse Case Management
  • 20. Passive - Proactive Current Passive State Risk Management Signal Detection Aggregate Reporting
  • 21. What can we do?
  • 22. What can we do?  Develop procedures for the identification, reporting and follow up of adverse drug events
  • 23. What can we do?  Assess the current technology used in the drug safety process and assist in implementation of new systems
  • 24. What can we do?  Evaluate data quality and data integrity controls in place
  • 25. What can we do?  Prepare risk minimization action plan (RiskMAP)
  • 26. What can we do?  Assess current drug safety and pharmacovigilance training programs
  • 27. What can we do?  Reconcile internal processes for recording safety data received from multiple sources
  • 28. For more information: Monica Dema, Manager New Business Development 973.658.3133 Or Monica.Dema@RCMT.com Or @MonicaDema